Om Nephade
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Om Nephade has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Abhijeet Grewal
Department of Orthopaedic Surgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA
1 shared publication - Alexander Yu
Department of Orthopaedic Surgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA
1 shared publication - John Joseph Corvi
Department of Orthopaedic Surgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA
1 shared publication - Jonathan James Huang
Department of Orthopedics Icahn School of Medicine at Mount Sinai New York New York USA
1 shared publication - Jun S. Kim
Department of Orthopaedic Surgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA
1 shared publication - Junho Song
Department of Orthopaedic Surgery, Icahn School of Medicine at Mount Sinai
1 shared publication
Latest Publications
- Open Access
- 10 April 2026
- Published by Asian Spine Journal (ASJ) in Asian Spine Journal
How statistically fragile are randomized controlled trial outcomes of balloon kyphoplasty for vertebral compression fractures?
Randomized controlled trials (RCTs) are essential for guiding the treatment of vertebral compression fractures with kyphoplasty, yet the statistical robustness of their findings has not been thoroughly evaluated. This systematic review assessed the fragility of dichotomous outcomes in kyphoplasty RCTs using the fragility index (FI), reverse fragility index (rFI), and fragility quotient (FQ). A comprehensive search of PubMed, Embase, and MEDLINE identified eligible RCTs, yielding 282 dichotomous outcomes for analysis. The overall median FI was 4 (interquartile range [IQR], 4-5), corresponding to a median FQ of 0.020 (IQR, 0.013-0.040). Statistically significant outcomes (n=18) demonstrated greater fragility, with a median FI of 2 (IQR, 1-4) and FQ of 0.015 (IQR, 0.011-0.029), compared with nonsignificant outcomes (n=264; FI, 5 [IQR, 4-5]; FQ, 0.020 [IQR, 0.013-0.041]). Subgroup analyses revealed that pain and complication outcomes had median FIs of 4 and 5, respectively, with FQs ranging from 0.016 to 0.025. Cement leakage outcomes were the most fragile (FI, 4; FQ, 0.048). More than half of the analyzed outcomes involved a greater number of patients lost to follow-up than their corresponding FI, underscoring the need for cautious interpretation of kyphoplasty trial results and supporting the inclusion of fragility metrics in future trial reporting to better inform clinical decision-making.
- 10 April 2026
- Published by Asian Spine Journal (ASJ) in Asian Spine Journal
Open AccessHow statistically fragile are randomized controlled trial outcomes of balloon kyphoplasty for vertebral compression fractures?
Randomized controlled trials (RCTs) are essential for guiding the treatment of vertebral compression fractures with kyphoplasty, yet the statistical robustness of their findings has not been thoroughly evaluated. This systematic review assessed the fragility of dichotomous outcomes in kyphoplasty RCTs using the fragility index (FI), reverse fragility index (rFI), and fragility quotient (FQ). A comprehensive search of PubMed, Embase, and MEDLINE identified eligible RCTs, yielding 282 dichotomous outcomes for analysis. The overall median FI was 4 (interquartile range [IQR], 4-5), corresponding to a median FQ of 0.020 (IQR, 0.013-0.040). Statistically significant outcomes (n=18) demonstrated greater fragility, with a median FI of 2 (IQR, 1-4) and FQ of 0.015 (IQR, 0.011-0.029), compared with nonsignificant outcomes (n=264; FI, 5 [IQR, 4-5]; FQ, 0.020 [IQR, 0.013-0.041]). Subgroup analyses revealed that pain and complication outcomes had median FIs of 4 and 5, respectively, with FQs ranging from 0.016 to 0.025. Cement leakage outcomes were the most fragile (FI, 4; FQ, 0.048). More than half of the analyzed outcomes involved a greater number of patients lost to follow-up than their corresponding FI, underscoring the need for cautious interpretation of kyphoplasty trial results and supporting the inclusion of fragility metrics in future trial reporting to better inform clinical decision-making.